Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

2/3期 进行中（已停止招募） NCT02839707

摘要

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens

Up to 28 days · Participants

Progression Free Survival (PFS) (Phase II)

From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years · months

PFS (Phase III)

From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years. · months

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Can — National Cancer Institute (NCI)

全部试验